A new study from the University of Aberdeen, published in Nature Communications, suggests that the rising use of weight loss medications such as Ozempic and Mounjaro could have far-reaching effects beyond individual health — potentially reshaping global food demand, prices, trade, and land use.

The research, conducted in collaboration with the University of Edinburgh and Scotland’s Rural College (SRUC), modelled scenarios of widespread uptake of GLP-1 receptor agonists for obesity. In the most ambitious scenario examined by the team, the study found that such medications could be associated with up to 6.6 million fewer deaths globally by 2050, alongside freeing around 32 million hectares of land currently used for agriculture and managed forestry. When combined with healthier diets, the potential benefits increased to 7.7 million fewer deaths and roughly 46 million hectares of land returned to non-agricultural use.

Dr Roslyn Henry, who led the study from the University of Aberdeen, said the findings suggest that changes in food consumption from these drugs could have consequences that extend beyond the individuals receiving treatment, including potentially reducing pressure on natural land in other parts of the world. However, she stressed that the results should not be interpreted as placing environmental responsibility on people living with obesity, nor as suggesting that medication is an environmental solution. The environmental impacts of what we eat, she noted, are shaped by the wider food system and not simply by individual choices.

Professor Peter Alexander of the University of Edinburgh, a co-author of the study, said that what we eat has consequences that ripple through global food systems, affecting what farmers produce, what countries trade, and how much land is needed for agriculture. As appetite-suppressing and other pharmaceutical treatments become more widely used, he said, it is important to understand how their uptake could reshape food systems and the resulting environmental and health outcomes.

The researchers emphasised that this work is a first exploratory assessment of the potential impact on the food system from widespread GLP-1 use, rather than a forecast of future treatment trajectories or a recommendation for universal treatment. They noted that alternative assumptions regarding adherence, treatment duration, changes in dietary intake, and weight regain could be explored in future work, particularly as treatment options and access evolve.

For university students, the study touches on several relevant themes. Those studying public health, environmental science, or economics may find the research a useful case study in how pharmaceutical trends can intersect with global systems. The findings also highlight the importance of policy decisions around food accessibility and sustainability — issues that could shape career opportunities in fields like nutrition policy, agricultural economics, and environmental advocacy. Students concerned about the environmental impact of their own diets may also see the study as a reminder that systemic changes, not just individual choices, drive food system outcomes.